Last updated on August 2018

Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction With Type 2 Diabetes Mellitus Study


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: NIDDM
  • Age: Between 20 - 85 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Asians aged from 20 to 85 years old at baseline
  • Patients with type 2 diabetes mellitus and including either A) or B) criteria.
    1. Patients necessary to start the treatment using anti-diabetic agent(s) or to change the anti-diabetic agent(s).
    2. Patients possible to change the anti-diabetic agent(s).
  • Patients with left ventricular ejection fraction more than 40%
  • Patients with written informed consent

Exclusion Criteria:

  • Patients with type 1 diabetes mellitus
  • Patients with slowly progressive type 1 diabetes mellitus positive for pancreatic islets related autoimmune antibody as GAD antibody or IA-2 antibody or ICA antibody
  • Patients with diabetes mellitus caused by evident genetic factors
  • Patients with diabetes mellitus caused by secondary factors as endocrine disease or liver disease
  • Patients with diabetic ketoacidosis or hyperosmolar hyperglycemic syndrome
  • Patients with any severe infectious diseases or planed any surgical treatments or suffered any severe traumas
  • Patients with severe liver dysfunction
  • Patients with hypophyseoprivic or adrenal insufficiency
  • Patients under malnutrition or starved state or irregular caloric intake or calorie insufficiency or hyposthenia
  • Patients judged to be unsuitable for the study as they are planning to exercise intensively
  • Patients judged to be unsuitable for the study as they may drink excessively or abuse drugs
  • Patients showing QT prolongation in the electrocardiogram
  • Patients with any past histories of heart failure showing NYHA classification grade more than 3 at baseline
  • Patients with any past histories of acute coronary syndrome or coronary intervention or cardiac surgery developed within 6 months
  • Patients with any surgical past histories of mitral valve replacement or mitral valve repair or severe calcification of mitral valve
  • Patients already treated with Teneligliptin
  • Women with breast-feeding
  • Pregnant women or patients who have possibilities of pregnancy
  • Patients expected to live less than 3 years
  • Patients with any past histories of drug hypersensitivity against Teneligliptin
  • Patients already involved in any other interventional clinical trials or planned to be involved
  • Patients judged to be inappropriate for the study by the doctors in charge

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.